This is a news story, published by Yahoo, that relates primarily to Zentalis Pharmaceuticals news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Zentalis Pharmaceuticals. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest cancer drug news, ovarian cancer trial news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
azenosertibReuters
•78% Informative
Zentalis Pharmaceuticals shares slumped about 30% to $ 5.88 in premarket trading.
The drug, azenosertib, was being tested against solid tumors in an early-stage study and in patients with a type of ovarian and uterine cancer.
The regulator's decision comes after two patients in the ovarian cancer study died due to presumed sepsis.
VR Score
88
Informative language
95
Neutral language
42
Article tone
formal
Language
English
Language complexity
63
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links